Fagancopeland5010

COVID-19 is a pandemic affecting mainly respiratory and gastrointestinal system. Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) binds angiotensin converting enzyme 2 (ACE-2) of renin-angiotensin system (RAS) resulting in hypokalaemia. We hereby report the a of hypokalaemic paralysis induced by COVID-19.

A 56 years old male with no co-morbidities presented with fever (2days), weakness in bilateral lower limbs (1 day). His had severe hypokalaemia with serum potassium of 2.05 mEq/L. RT-PCR of nasopharyngeal swab for SARS-CoV- 19 was positive. He was diagnosed as a case of hypokalaemic paralysis induced by COVID-19 infection.

We suggest that during this pandemic era if a COVID-19 patient presents with paralysis, hypokalaemia induced paralysis should be kept in the differential diagnosis.

COVID-19 infection leads to hypokalemia.

Hypokalaemic paralysis as a manifestation of COVID-19.

Hypokalaemic paralysis as a manifestation of COVID-19.Pregnant women are one of the most important groups who need special attention during this Covid-19 pandemic. Women's physiological changes in the immune system during pregnancy put them and their neonates at increased risk of negative outcomes of COVID-19 infection but the data is still scarce to comment upon. A case of asymptomatic SARS-CoV-2 infected mother and its effect on neonate is reported. This is the first case where the evidence of cytokine storm in neonate has been demonstrated in the presence of transplacental acquired IgG antibodies.Tight glycemic control has been recognised as the cornerstone of modern diabetes management. Until recently, glycated hemoglobin (HbA1c) was the only reliable tool for measuring glycemic control, but it is not an ideal metric as it is retrospective, unable to pick up hypo- and hyperglycemic excursions and prone to interference by conditions such as anemia and hemoglobinopathies. The advent of continuous glucose monitoring systems is a giant leap in diabetes management as it enables visualisation of glucose trends over periods of time, helping in identification of hypo- and hypoglycemic events and enabling appropriate treatment decisions to be made. The recent launch of the real-time patient CGM in India is a further step in the right direction as it will empower patients to take control of their diabetes by providing them information on their glucose levels and trends in real time.

Management of diabetes in India remains less than satisfactory despite a huge prevalence of type 2 diabetes (T2D). Associated obesity, inadequate lifestyle modifications and burden of treatment costs are certain major issues contributing to inadequate management of diabetes in India.

To evaluate the use of Teneligliptin in patients with diabetes and its safety, efficacy and cost effectiveness especially in Indian patients with T2D.

A detailed analysis of the best available scientific evidence (clinical trials, meta-analyses and real-world experience) was performed to create an evidence driven understanding of teneligliptin's efficacy, safety and cost effectiveness. Fourteen leading endocrinologists contributed as experts and the modified Delphi process was followed. Evidences and clinical questions were discussed over a series of web and in a live meeting. Final draft was created based on the opinions endorsed by the experts.

Teneligliptin is the most commonly used gliptin in India and exhibits pharmaioned itself as a very important drug in the armamentarium for managing T2D. Proteasome inhibitor It offers efficacy, safety and cost-effective therapeutic choice in Indian patients with T2D.

Teneligliptin has firmly positioned itself as a very important drug in the armamentarium for managing T2D. It offers efficacy, safety and cost-effective therapeutic choice in Indian patients with T2D.

Stroke is the second leading cause of death and third most common cause of disability-adjusted life years in the world. Atherosclerosis plays a key role in the pathogenesis of stroke and inflammation is central in the initiation, progression and complications of atherosclerosis by mediating every stage of atheroma development. High platelet counts may increase thrombocyte activation and aggravate the release of inflammatory mediators. In contrast, lymphocytes exert anti-inflammatory response in atherosclerosis development. The advantage of platelet to lymphocyte ratio (PLR) is that it reflects the condition of both inflammation and thrombosis pathways and is more valuable than either platelet or lymphocyte counts alone. This emerging marker has not been frequently studied with acute ischemic stroke; hence aim of the present study was to find out the role of PLR (Platelet to lymphocyte ratio) in patients of acute ischemic stroke and correlating with NIHSS for predicting the prognosis.

100 cases of AIS and t effective and easily obtainable novel inflammatory marker that may help in predicting the severity of disease and prognosis in terms of functional outcome as evidenced by its increased value in patients of acute ischemic stroke as well as its linear positive correlation with NIHSS score.

Platelet to lymphocyte ratio (PLR) is a simple, cost effective and easily obtainable novel inflammatory marker that may help in predicting the severity of disease and prognosis in terms of functional outcome as evidenced by its increased value in patients of acute ischemic stroke as well as its linear positive correlation with NIHSS score.

Stroke in COVID-19 has been reported in critically ill patients globally. Stroke as a singular manifestation of COVID-19 in absence of typical symptoms (fever, cough and dyspnea) is under- recognized.

Comparative study of clinical and laboratory parameters of COVID-19 stroke patients without typical symptoms at onset with stroke cases without COVID-19 infection.

28consecutive stroke patients, eight with coronavirus infection and twenty without COVID-19 admitted to neurology department of a tertiary care centre of North West India between 20 June,2020 and 19 July,2020 were enrolled in this retrospective study.

COVID-19 patients had higher frequency of seizures (4[50%]) vs 2[10%];p= 0.03)and altered mental status(6[75%] vs 6[30%] p= 0.04). Severity of ischemic stroke(NIHSS >20, 3[75 %] vs 2[18%])and mortality(p=0.04)despite comparable vascular risk factors for stroke between the two groups was higher in COVID-19 patients. Three out of four COVID-19 young strokes died. Two females with COVID-19 did not develop any typical symptoms, six males(75%) developed fever with dyspnea after a mean delay of 2.